Schutyser Evemie, Struyf Sofie, Van Damme Jo
Laboratory of Molecular Immunology, Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium.
Cytokine Growth Factor Rev. 2003 Oct;14(5):409-26. doi: 10.1016/s1359-6101(03)00049-2.
CCL20, alternatively named liver and activation-regulated chemokine (LARC), macrophage inflammatory protein-3alpha (MIP-3alpha) or Exodus-1, is the only chemokine known to interact with CC chemokine receptor 6 (CCR6), a property shared with the antimicrobial beta-defensins. The ligand-receptor pair CCL20-CCR6 is responsible for the chemoattraction of immature dendritic cells (DC), effector/memory T-cells and B-cells and plays a role at skin and mucosal surfaces under homeostatic and inflammatory conditions, as well as in pathology, including cancer and rheumatoid arthritis. In this review, the discovery, the gene and protein structure, the in vitro biological activities, the cell and inducer specific expression and the tissue distribution of CCL20 and CCR6 are discussed.
CCL20，别名肝与激活调节趋化因子（LARC）、巨噬细胞炎性蛋白-3α（MIP-3α）或外渗素-1，是已知唯一能与CC趋化因子受体6（CCR6）相互作用的趋化因子，这一特性与抗微生物β-防御素相同。CCL20-CCR6配体-受体对负责未成熟树突状细胞（DC）、效应/记忆T细胞和B细胞的化学趋化作用，在稳态和炎症条件下的皮肤和黏膜表面以及包括癌症和类风湿关节炎在内的病理过程中发挥作用。在这篇综述中，将讨论CCL20和CCR6的发现、基因和蛋白质结构、体外生物学活性、细胞和诱导剂特异性表达以及组织分布。
